Bold claim: Mark Cuban wants Trump to back a policy that could reshape Drug pricing and spur U.S. generics production. Here’s what’s at stake and why it matters.
Mark Cuban is publicly urging the Trump administration to eliminate the substantial regulatory fees the U.S. Food and Drug Administration (FDA) charges for generic drug approval applications. He conveyed this appeal to Reuters, outlining how waiving these fees could unlock faster and larger-scale domestic manufacturing of generic medicines.
Cuban’s proposal centers on Cost Plus Drugs, his online pharmacy that already sells medications to consumers at reduced prices. He indicates that if the FDA’s fees were removed, Cost Plus Drugs could accelerate and expand U.S. manufacturing of certain generics from its Dallas facilities within roughly a year. The plan would focus on high-cost generics, including rare-disease therapies that currently can cost patients hundreds of thousands of dollars, as well as widely used generic medicines.
Currently, the FDA charges roughly $360,000 per generic drug approval application. Cuban argues that for a portfolio of hundreds of medicines, these fees accumulate to a level that jeopardizes the economics of shifting production from overseas back to the United States. Eliminating or waiving these fees could make domestic production financially viable and encourage more drug manufacturing on American soil.
Trump has framed his political program around restoring manufacturing jobs and reshoring critical industries, including pharmaceuticals and their active ingredients. As part of that broader agenda, drugmakers have pledged to invest hundreds of billions to expand U.S. production and to reduce prices for several branded drugs to mitigate tariff concerns.
Cuban notes that Cost Plus Drugs already operates a major compounding facility delivering sterile injectables and other hospital medicines. If policy changes pass, the company would repurpose and expand its Dallas operation to manufacture generic medicines, targeting both high-cost generics and widely used options alike. He emphasizes a practical distinction: there is little value in producing inexpensive $4 generics domestically unless there is a pathway to meaningfully lower prices for more expensive treatments.
Historically, Cuban has championed price transparency in healthcare and scrutinized middlemen who negotiate rebates with drugmakers. He indicates Cost Plus Drugs plans to publish its provider contracts as a benchmark for industry-wide transparency while continuing to pursue additional cost-reduction initiatives. He also referenced Cost Plus Drugs’ involvement with TrumpRx, a government-supported initiative intended to connect patients directly with manufacturers to drive down costs.
Why this matters: If the FDA fee structure were adjusted or waived, the economics of U.S. generics manufacturing could shift, potentially increasing domestic production and reducing patient costs for many medicines. Yet the policy proposal invites debate: does waiving fees create a level playing field or undercut regulatory safeguards? Will shifting generics production to the U.S. reliably lower prices for consumers across the board, or could it distort competition and investment incentives?
What do you think? Should FDA generic-approval fees be waived to incentivize domestic manufacturing, or could alternative approaches—such as targeted subsidies, tax incentives, or price negotiations—be more effective and less controversial? Share your views in the comments.
